Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.

Isik E. G., Has-Simsek D., Sanli O., Sanli Y., Kuyumcu S.

Clinical nuclear medicine, vol.47, no.1, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.1097/rlu.0000000000003837
  • Journal Name: Clinical nuclear medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Keywords: FAPI, PSMA, theranostics, mCRPC, cancer-associated fibroblast, Ga-68-FAPI04
  • Istanbul University Affiliated: Yes


Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent Ga-68-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent F-18-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using Ga-68-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.